This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Health stocks amassed greater losses Thursday amid disappointing profit reports from several companies.

The Nasdaq biotechnology index, with 165 stock components, fell 11.6, or 1.5%, to 776.52 on Thursday. The index has been facing a swoon in the past week, down 4.7% since last Thursday's open.

Among individual stocks Thursday, earnings were in focus. 3SBio (SSRX) shares plummeted after the biotech company's fourth-quarter earnings and 2008 revenue forecast missed estimates. The company after the close Wednesday reported quarterly earnings of $2.4 million, or 11 cents per American depository share, shy of analysts' average target of 13 cents per ADS.

3SBio said it expects revenue in 2008 to range from $30 million to $32 million, while analysts had forecast a top line of $36.3 million. Shares tumbled $3.31, or 28.3%, to $8.39 on Thursday.

Quest Diagnostics (DGX - Get Report) fell 5% after the testing company gave 2008 guidance below the Street view. The company said it expects to earn between $3 and $3.20 a share, while analysts forecast a profit of $3.36 a share.

For its last quarter, Quest reported a loss of $5.3 million, or 3 cents a share, reversing a year-earlier profit of $149.3 million, or 76 cents a share, in the year-ago quarter. When charges are factored out, the company's earnings of 79 cents a share beat analysts' estimates by a penny. Shares slipped $3.81, or 7.3%, to $48.35.

Also on the downside was Ligand Pharmaceuticals (LGND - Get Report), which fell 13% to a 52-week low after its profit report. The drug company reported fourth-quarter net income of $5.9 million, or 6 cents a share, down from $141.4 million, or $1.61 a share, in the year-ago quarter. Shares slid 50 cents, or 12.5%, to $3.51.

Elsewhere, Psychiatric Solutions (PSYS) shares tumbled after the behavioral-health services company beat earnings estimates by a penny, but fell shy on revenue. The company recorded a fourth-quarter profit of $23.2 million, or 42 cents a share, up from $17.6 million, or 33 cents a share, during the same period a year prior. Analysts expected a 41-cent-a-share profit. Psychiatric Solutions registered revenue of $403.4 million, while analysts were looking for $413.6 million.

For 2008, the company expects earnings $1.93 and $1.97 a share, above Wall Street's target of $1.88. For the first quarter, however, Psychiatric Solutions forecast earnings of 42 cents to 43 cents a share, a penny short of estimates. Its shares dropped $4.03, or 12.7%, at $27.65.

Heading the other direction, Icon (ICLR - Get Report), which provides outsourced development services, to pharma, biotech and medical device companies, gained $7.02, or 11.2%, to $69.64, on a stronger-than-expected earnings report.

The company reported fourth-quarter net income of $15.9 million, or 53 cents a share, up from $11.4 million, or 39 cents a share, in the year-ago period. Revenue climbed 40% to $180.7 million. The results beat Thomson Financial's average analyst estimate for earnings of 50 cents a share and revenue of $172.5 million.

CryoLife (CRY - Get Report) also gained after posting earnings that topped estimates. The company said fourth-quarter earnings rose to $2.6 million, or 10 cents a share, from $50,000, or a penny a share, a year earlier. Revenue rose 19% to $25.1 million. Analysts forecast earnings of 6 cents a share on revenue of $24.1 million. CryoLife's stock surged $1.06, or 11.8%, to $10.03.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PSYS $0.89 0.00%
CRY $10.27 0.00%
DGX $63.66 0.00%
ICLR $71.00 0.00%
LGND $89.24 0.00%


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs